Observational methods for COVID-19 vaccine effectiveness research: a trial emulation and empirical evaluation

Martí Català1 , Edward Burn1 , Trishna Rathod-Mistry¹ , Junqing Xie1 , Antonella Delmestri1 , Daniel Prieto-Alhambra^{1,2*}, Annika M. Jödicke¹

 1 د کند.
Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Nether
Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Nether Musculos Constant Sciences, University of Oxford, UK
Pepartment of Medical Informatics, Erasmus Unive

department of Medical Information of Medical Information Medical Information Medical Center, Rotterdam, Netherlands
Property Medical Center, Rotherlands and Netherlands and Netherlands and Netherlands and Netherlands and N $\ddot{ }$ \overline{C}

Abstract

Despite much research on the topic, little work has been done comparing the use of methods to control for confounding in the estimation of COVID-19 vaccine effectiveness in routinely collected medical record data. We conducted a trial emulation study to replicate the ChAdOx1 (Oxford/AstraZeneca) and BNT162b2 (BioNTech/Pfizer) COVID-19 phase 3 efficacy studies. We conducted a cohort study including individuals aged 75+ from UK CPRD AURUM ($N = 916,128$) in early 2021. Three different methods were assessed: Overlap weighting, inverse probability treatment weighting, and propensity score matching. All three methods successfully replicated the findings from both phase 3 trials, and overlap weighting performed best in terms of confounding, systematic error, and precision. Despite lack of trial data beyond 3 weeks, we found that even 1 dose of BNT162b2 was effective against SARS-CoV-2 infection for up to 12 weeks before a second dose was administered. These results support the UK Joint Committee on Vaccination and Immunisation modelling and related UK vaccination strategies implemented in early 2021. modelling and related UK vaccination strategies implemented in early 2021.

Key messages

- Real world evidence generated using weighting (overlapping weights and inverse probability of treatment weights) and propensity score matching: all methods successfully replicate the findings of Phase 3 trials for COVID-19 vaccine effectiveness.
- Overlap weighting provides the least biased estimated • amongst the most suitable methods for future COVID-19 vaccine effectiveness research.
- amongst the most suitable methods for future COVID-19 vacance effectiveness research. • protection against SARS-COV-2 infection for up to 12 weeks, in line with UK's Joint Committee on protection against SARS-COV-2 infection for up to 12 weeks, in line with UK's Joint Committee on
Vaccination and Immunisation modelling and subsequent vaccination strategies. Vaccination and Immunisation modelling and subsequent vaccination strategies.

It is made available under a CC-BY 4.0 International license.

Introduction

Following the start of the COVID-19 vaccination programs, routinely collected data are being widely
used to evaluate the effectiveness and safety of COVID-19 vaccines(1-4) and boosters(5, 6). However, careful consideration of how-to best account for confounding is required when comparing vaccinated and unvaccinated people: Aside from people's individual characteristics, particularly age and co-morbidities associated with higher risk of severe COVID-19, population-level confounder such as the location, i.e. level of community transmission, and vaccination period are among the most important confounders. However, the latter were not always adequately considered in many of the previously conducted vaccine effectiveness studies. Differences in methods for adjustment for confounders as well as choice of study design, inclusion criteria and calendar time can have substantial impact on the findings and their interpretation as highlighted in recent observational studies(7, 8) assessing the comparative effectiveness of $ChAdOx1$ (Oxford/AstraZeneca) and BNT162b2 (BioNTech/Pfizer) using routinely-collected data from UK: a 28% (95% CI, 12-42) decreased risk for infection after first dose vaccination with BNT162b2(8) vs. no differences in infection incidence between the two COVID-19 vaccines (7). Another challenge when studying vaccine effectiveness is the handling of the immediate time after the first vaccine dose. Randomised trials (9, 10) showed no protective vaccine effect in the first 2 weeks, with the vaccine-induced immunity still building up. However, while some observational studies could replicate these findings (1) , others already observed protective effects in the early days $(11, 12)$, indicating the presence of residual confounding. However, some studies and even trials omitted this vulnerable time from their main analyses (10) while others did not (9), which makes it difficult to compare results across m matrices (10) which makes it distributes to compare results across the compare results across the compare results across m studies.
While several methods were used in previous studies, a rigorous assessment of their ability to

resolve confounding has not yet been completed(13). Our study provides an empirical evaluation of the comparative performance of different weighting and matching methods to minimise confounding in the study of COVID-19 vaccine effectiveness: overlap weighting (14) , inverse probability of treatment weights(15), and propensity score with exact geographic and index date matching. To do this, we measured confounding based on imbalances between vaccinated vs unvaccinated subjects in terms of all recorded variables in the patient's records. Additionally, we used negative control outcomes to identify systematic error due to unobserved confounders. Lastly, we conducted target trial emulations to compare our findings to those from the BNT162b2(9) and $ChAdOx1(10)$ phase 3 randomised controlled trials. As no trials assessed the effect of BNT162b2 between 3 and 12 weeks following the first dose, we estimated vaccine effectiveness based on between 3 and 12 weeks following the first dose, we estimated vacant dose, we estimated vacant dose, we estima

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

primary care data and compared our results to the models the Joint Committee on Vaccination and
Immunisation (JCVI) used to inform the vaccination campaign in the UK in early 2021(16). Immunisation (JCVI) used to inform the vaccination campaign in the UK in early 2021(16).

It is made available under a CC-BY 4.0 International license.

Methods

Study type, setting, and data source
A cohort study was conducted using UK NHS primary care data from the Clinical Practice Research Datalink (CPRD) AURUM, mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) (17).

Study population

All people aged \geq 75 years, who were not previously infected with or vaccinated against SARS-CoV-2 and were registered in CPRD AURUM for \geq 180 days before study start (04/01/2021) were eligible for inclusion. Subsequently, individuals were assigned to the vaccinated (VC) or unvaccinated (UV) cohort, based on whether they were vaccinated against COVID-19 between 04/01/2021 and 28/01/2021 (both dates included). Two different vaccinations were recorded at that time in England(18): BNT162b2 (BioNTech/Pfizer) and ChAdOx1 (Oxford/AstraZeneca). We therefore constructed three different vaccinated cohorts: any type of vaccination cohort (VC), ChAdOx1 vaccinated cohort (AZ), and BNT162b2 vaccinated cohort (PF). Index date for individuals in the vaccinated cohort was their vaccination date. All individuals who had a record of both vaccines at the index date were excluded. Assignment of the index date for unvaccinated people depended on the method used to account for confounding, i.e. matching or weighting. For matching, the index date of the matched counterpart was used; whereas for PS weighting, index dates for unvaccinated people were randomly assigned following the distribution of index dates in the vaccinated cohort, as depicted in Figure 1. In supplementary material Figure S1 distribution of index dates for vaccine type effectiveness are shown. After assignment of the respective index dates, individuals with a recording of COVID-19 infection before or on index date and individuals vaccinated before index date were
excluded. $\boldsymbol{\epsilon}$ Covid-19 infection before or on individuals vaccinated before individuals vaccinated before index date were index da

Exposure/s of interest

Each of the three identified vaccinated cohorts (VC, PF, AZ) were compared with an unvaccinated cohort (UV) to study vaccine effectiveness after weighting or matching. cohort (UV) to study vacante effectiveness after weighting or matching.
Follow-up

Follow-up
Individuals were censored when: they received another vaccination dose (vaccinated cohorts) or received the first vaccination dose (unvaccinated); left the CPRD AURUM database; or they died. received the first vaccination dose (university of the CPRD AURUM database; or the CPRD AURUM database; or the
The CPRD AURUM database; or they died. Aurum database; or they died. Aurum database; or they died. Aurum datab

Primary Outcomes
Two clinical outcomes were ascertained, in line with primary outcomes in the target phase 3 trials for the vaccines: (i) COVID-19 PCR, defined by a positive COVID-19 PCR test; and (ii) COVID-19 for the vacuum ϵ , defined by a positive ϵ , and ϵ positive COVID-19 PCR test; and (ii) covid-19 ϵ It is made available under a CC-BY 4.0 International license.

PCR/diagnosis, defined by either a COVID-19 diagnosis or a positive COVID-19 test. Definitions of the
clinical outcomes can be found in supplementary material Tables S1-3.

clinical outcomes can be found in supplementary material Tables S1-3.
Control Outcomes

Control Outcomes PCR testing

We used PCR testing (e.g. performed COVID-19 PCR test regardless of test result) as a control
outcome and proxy for diagnostic effort. We would expect this to be non-differential with respect to
vaccination. outcome and proxy for diagnostic effort. We would expect this to be non-differential with respect to

vaccination. Negative control outcomes (NCO)

Additionally, a total of 43 NCO were pre-specified based on previous methodological research on
vaccine safety(19) and refined after review by two clinical epidemiologists (DPA and AMJ). NCO are outcomes not causally associated with the exposure of interest, here COVID-19 vaccine/s exposure. Detail on the 43 utilised NCO is provided in the supplementary material Table S4.

Detail on the 43 utilised NCO is provided in the supplementary material Table S4.

<u>---------------------</u>
Propensity Score

Large-scale Propensity Scores (PS) were used to minimise confounding. PS represent the probability
of exposure based on a participant's baseline characteristics. Covariates to be included in the PS equation were extracted, including condition occurrences for three different time windows (1 to 30 days, 31 to 180 days, and 181 days to any time prior index date), and drug exposures for 2 time periods (1 to 30 days, 31 to 180 days prior index date). Subsequently, all covariates with a frequency $>0.5%$ were included in a lasso regression, which was used to identify relevant confounders to be included in the large-scale PS. In addition, the following variables were forced into the PS model as they were known to be associated with vaccination in the UK: location (region identifier; 9 different regions; or General Practice (GP) surgery identifier; 1357 different GP); age (5-year bands and as a continuous variable using a polynomial to account for non-linearity); prior observation years; number of GP visits, and number of previous COVID-19 PCR tests during each of the three periods (1 to 30-day, 31 to 180-day and 181 days to any time before index date).

PS Weighting and Matching

Regional vaccination, testing, and COVID-19 incidence rates(20) on index date were forced into the PS. Index date was also forced into the PS to ensure that the balance is maintained. PS were computed using a logistic regression model, with 3 different representations of location: without location (PS_{pase}), location defined as region (PS_{ree}) or de-identified GP surgery (PS_{GP}). We used two location (PSbase), location defined as region (PS-reg) or de-identified GP surgery (PSGP). We use $\frac{1}{2}$ It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

different weighting methods: Inverse Probability of Treatment Weighting (IPTW), with trimming over
0.95 and above 0.05; and Overlap Weighting (OW)(21).

As for Matching, we used 1:1 PS nearest neighbours matching with exact matching on age band, gender, and location (region or GP) with caliper width 0.2 SD on the PS as calculated on their index date (PS₁). Matched unvaccinated individuals were assigned the same index date as their vaccinated pair. PS were computed again on the new index date after matching ($PS₂$) to ensure that the matching was still balanced after the index date assignment.

The following metrics were used to assess the performance of the different methods:

- (1) Covariate imbalance as a proxy of measured confounding was assessed by calculating standardized mean differences (SMD) between compared cohorts after weighting or standardized mean differences (SMD) between compared control after weighting or
matching.
- matching.
(2) Minimum detectable relative risk (MDRR) was computed for a 95% confidence interval, power of 0.8, a 10-day cumulative incidence of 0.0067, and 10 days of following time.
- (3) Association between vaccination status and Negative Control Outcomes (NCO)(22) was estimated using Cox proportional hazard regression to detect unmeasured confounding.
- (4) Association between vaccination status and COVID-19 PCR/diagnosis in the first 10 days following vaccination was estimated using Cox proportional hazard regression to detect unmeasured confounding through comparison with results from vaccination trials(9). unmeasured conforming through comparison with results from vacanation trials₍₉₎.
Il calibration

Empirical calibration
Hazard ratios calculated for (1) PCR testing, (2) COVID-19 PCR and (3) COVID-19 PCR/diagnosis were calibrated with the result of the NCO analysis as described in Schuemie et al.(23). calibrated with the result of the NCO analysis as described in Schuemie et al.(23).

Target trial emulations
We aimed to reproduce the effectiveness observed at 3 weeks after vaccination in the BNT162b2 and in the ChAdOx1 phase 3 trials $(9, 10)$ and the estimated effectiveness at 12 weeks for BNT162b2. For the AstraZeneca trial emulation, individuals who tested positive or were censored before the $24th$ day were eliminated from the analysis in line with the trial's statistical analysis plan and protocol(10). We deemed a target trial as successfully replicated when the confidence intervals from the trial and observational data overlapped. It is worth noting that the 12-week trial estimate of vaccine effectiveness for BNT162b2 was based on an extrapolation by the UK JCVI committee, and did not report confidence intervals(16). Estimates from observational data were obtained using the method yielding lowest confounding (lower SMD values and least number of statistically significant NCO) and better statistical power (narrower MDRR). NCO) and better statistical power (narrower MDRR).

It is made available under a CC-BY 4.0 International license.

Patient and Public Involvement

A patient representative was involved in the design of the project.

It is made available under a CC-BY 4.0 International license.

Study population and characteristics

Following application of inclusion criteria, 583,813 vaccinated individuals (348,275 PF and 235,538
AZ); and 332,315 unvaccinated participants were identified (Figure 2). OW weighting methods retained the largest sample size, with a total of 905,418 participants included for analysis. IPTW led to the inclusion of the second largest number of participants, with $N=903,147$ for IPTW-PS_{hase} $N=902,958$ for IPTW-PS_{reg}, and N=856,636 for IPTW-PS_{GP}. Due to the exclusion of unmatched people, matching methods led to a substantially reduced sample size: N=459,000 for matchingreg; N=369,310 for matching_{ge}. Population flowcharts stratified by vaccine type are available in supplementary
material Figures S2-3. for external figures S2-3. Population flowcharts stratified by vaccine type are available in supplementary $\frac{1}{2}$

Baseline characteristics before weighting/matching are shown in Table 1. Relevant differences (SMD>0.1) between vaccinated and unvaccinated cohorts included age, location (region and GP practice) and number of GP visits in the previous 180 days. Additionally, differences were noted for comorbidities heart disease, hypertensive disorder, malignant neoplastic disease, and renal impairment. Supplementary material Tables S5-7 provide detail on a total of 23 imbalanced confounders with SMD > 0.1 in the comparison of vaccinated vs unvaccinated, 25 in AZ vs unvaccinated, and 27 in PF vs unvaccinated cohorts. unvaccinated, and 27 in PF vs unvaccinated cohorts.

Figure 2. Cohorts building howerialt in any type of vaccination and anvaccinated companison. (A) Flowchart to build the different weighting cohorts, the start point of these cohorts is the end of panel A. Dark blue number any type of vacemation (VC) and unvaccinated (VV) initial cohorts. (B) Flowchart to build the different particle in the transformated of these cohorts and light for unvaccinated. (C) Flowchart to build the different match unvaccinated. (C) Flowchart to build the different matching cohorts, the start point of these cohorts is the end of panel A.
PS₁ and PS₂ are the propensity scores (PS) computed at the start and index date, respectivel PS₁ and PS₂ are the propensity scores (PS) computed at the start and index date, respectively. *At this step individuals with a record of both ChAdOx1 and BNT162b2 vaccines at the index date were excluded.

This step individuals with a step individuals with an individual step individuals with the start and individuals with the step individuals wi

It is made available under a CC-BY 4.0 International license.

Table 1. Baseline differences between unvaccinated cohort and the vaccinated cohorts before weighting/matching. The
different covariates included in this table are computed at the start date (4th Jan) for each individual different covariates included in this table are computed at the start date (4th Jan) for each individual. Age and prior
observation time are measured in years. Region and General Practice (GP) surgery are the location iden

$\overline{}$

Comparison of performance of PS methods
Minimum detectable relative risks (MDRR) were computed for each of the comparison and methods as a proxy for statistical power and are reported in Table 2. As expected, the study was well powered due to large sample sizes, and MDRR was closer to one (better power) for weighting (e.g. MDRR 0.93 to 1.08 for IPTW in the 'any vaccine' analysis), and slightly further away for the one (worse power) $\frac{1}{2}$ for $\frac{1}{2}$ for $\frac{1}{2}$ for the one (worse power), and slightly further away for the one (worse power), and slightly further away for the one (worse power), and $\frac{1}{2}$ It is made available under a CC-BY 4.0 International license.

for matching (e.g. MDRR 0.86 to 1.17 for matching_{gp} in the 'any vaccine' analysis). This relates to the
exclusion of unmatched participants in the latter (see Figure 2). Standardized mean differences (SMD) and the number (%) of NCO associated with exposure are also reported in Table 2, as a proxy for measured/observed and unmeasured confounding, respectively. Both were highest in the unweighted analysis, and lowest in matching and OW compared to IPTW. Accounting for GP practice minimised confounding further: e.g. maximum SMD went from 0.79 in IPTW PSbase to 0.15 in IPTW PS_{gp}. Overall, OW PS_{gp} and matching_{gp} were the best methods in terms of observed and unobserved confounding minimisation, measured by SMD and NCO respectively.

Table 2. Minimum detectable relative risk (range); standardized mean differences (mean, standard deviation, and maximum for all the identified covariates); and number of significative negative control outcomes (positive and negative;
regarding if they are positively or negatively associated with the exposure).

regarding if they are positively or negatively associated with the exposure).					
Method	Minimum detectable relative risk	Standardized mean differences		Significant (p<0.05) negative control outcomes	
		mean±STD	maximum	N(%) with RR>1	N(%) with RR<1
Any type of vaccinated comparison					
unweighted	$[0.93 - 1.08]$	0.023 ± 0.029	0.74	32 (74%)	1(2%)
IPTW PS base	$[0.93 - 1.08]$	0.004±0.019	0.79	21 (49%)	7 (16%)
IPTW PS _{reg}	$[0.93 - 1.08]$	0.004±0.018	0.78	20 (47%)	6 (14%)
IPTW PS _{gp}	$[0.92 - 1.08]$	0.004 ± 0.005	0.15	26 (60%)	6 (14%)
OW PS _{base}	$[0.93 - 1.08]$	0.002 ± 0.019	0.81	8 (19%)	4 (9%)
OW PS _{reg}	$[0.93 - 1.08]$	0.002 ± 0.019	0.80	8 (19%)	4 (9%)
OW PS _{gD}	$[0.93 - 1.08]$	0.002 ± 0.002	0.03	8 (19%)	3(7%)
$matching_{\text{reg}}$	$[0.87 - 1.15]$	0.005 ± 0.006	0.19	17 (40%)	4 (9%)
m atching $_{gp}$	$[0.86 - 1.17]$	0.007 ± 0.006	0.05	17 (40%)	3(7%)
AstraZeneca vaccinated comparison					
unweighted	$[0.86 - 1.16]$	0.023±0.029	0.82	32 (74%)	1(2%)
IPTW PS _{base}	$[0.86 - 1.16]$	0.003±0.020	0.85	16 (37%)	4 (9%)
IPTW PS _{reg}	$[0.86 - 1.16]$	0.003±0.020	0.84	17 (40%)	4 (9%)
IPTW PS _{gp}	$[0.86 - 1.16]$	0.003 ± 0.004	0.13	17 (40%)	4 (9%)
OW PS _{base}	$[0.86 - 1.16]$	0.002±0.020	0.86	5(12%)	1(2%)
OW PS _{reg}	$[0.86 - 1.16]$	0.002 ± 0.020	0.85	5(12%)	1(2%)
OW PS _{gp}	$[0.86 - 1.16]$	0.001 ± 0.002	0.02	5(12%)	2(5%)
$matching_{reg}$	$[0.85 - 1.18]$	0.004 ± 0.006	0.13	10 (23%)	2(5%)
Matching _{gp}	$[0.82 - 1.21]$	0.005 ± 0.005	0.04	10 (23%)	2(5%)
Pfizer vaccinated comparison					
unweighted	$[0.89 - 1.12]$	0.024±0.036	0.99	30 (70%)	1(2%)
IPTW PS base	$[0.90 - 1.12]$	0.003±0.024	1.04	19 (44%)	4 (9%)
IPTW PS _{reg}	$[0.90 - 1.12]$	0.003 ± 0.024	1.03	18 (42%)	4 (9%)
IPTW PS _{GP}	$[0.89 - 1.12]$	0.003 ± 0.005	0.18	26 (60%)	5(12%)

It is made available under a CC-BY 4.0 International license.

.
F Figure 3 depicts SMD values for the weighted cohorts. Despite PS weighting, the GP practice
covariate was only balanced using OW with PS_{GP}. IPTW did not yield sufficient balance for GP practice in any of the estimated PS, as noted by SMD>0.1. Similar findings were seen for region, which was not balanced in any of the weighting methods unless location was included in the model. Matching at regional level did not yield sufficient balance for GP. In fact, only matching_{gp} and OW PS_{gp} were able to minimize GP unbalance. OW performed better than IPTW and matching in terms of overall covariate balance, with lower minimum SMD for all covariates (Table 2). Supplementary material Figures S4 and S5 show the SMD balancing for the Pfizer and AstraZeneca vs unvaccinated
comparisons. $\sum_{i=1}^{\infty}$ show the SMD balancing for the SMD balancing for the Pfizer and AstraZeneca vs unvariated vs u

Figure 3. Standardized mean differences (SMD) for the different methods in any type of vaccination and unvaccinated
comparison. (A) Scatter plot to compare before (unadjusted) and after (adjusted) weighting. Region and GP only covariates that remain unbalanced after many of the weightings. (B) Boxplot for the covariates smd after matching.
Only GP surgery is unbalanced after regional matching. only GP surgery is unbalanced after regional matching.
Only GP surgery is unbalanced after regional matching. Only GP surgery is unbalanced after regional matching.

It is made available under a CC-BY 4.0 International license.

Figure 4 depicts the results of NCO analyses. In general, OW showed lower systematic error than
IPTW and matching in most scenarios. Unweighted analyses show, as expected, clear evidence of one-sided systematic error, with many negative control outcomes being positively associated (RR>1) with vaccine exposure (Table 2). Supplementary material Figures S6 and S7 show the NCO results for the Pfizer and AstraZeneca vs unvaccinated comparisons.

Figure 4. Negative control outcomes (NCO) hazard ratios and standard deviation. Each blue dot represents a different
NCO. Purple dashed are the significative threshold for the NCO; they are positively correlated if they ar

dashed line and negatively on the left. Orange lines mark significance thresholds after calibration.
In addition to the pre-specified NCO, Figure 5 shows the observed HR for the control outcome of PCR
testing) and for the dealer and negatively on the line and negatively on the left. Orange lines mathematical into the left. Orange lines mathematical outcomes (PCR+ and PCR+ or diagnosis) at day 10 and the lines of the calibration. The lines o $\frac{1}{\sqrt{2}}$ testing) and for the clinical outcomes (PCR+ and PCR+ or diagnosis) at day 10 after the first dose of vaccine. Although unweighted analyses led to a biased estimate (HR>1) for PCR testing, all weighting and adjustment methods resolved this and led to a calibrated HR including the expected null effect (HR=1). Unexpectedly, all the tested methods showed a protective effect against both clinical outcomes in the first 10 days after first-dose vaccination. The numerical values of Figure 5 can be outcomes in the first 10 days after first-dose vaccination. The numerical values of Figure 5 can be It is made available under a CC-BY 4.0 International license.

observed in supplementary material Table S8. In supplementary material Figure S8 and Table S9 we
can observe the same analysis than in Figure 5 without the 10 days censoring.

The Kaplan-Meier plots using Overlapping Weights and PS_{GP} for the three studies comparisons can be observed in supplementary material Figure S9 (COVID-19 PCR + diagnosis) and Figure S10 (COVID-
19 PCR).

Figure 5. Hazard ratio for the control outcomes censoring at day 10. Each dot is the hazard ratio (HR) for a different adjustment computed with a Cox proportional hazards regression. Blue lines are for any type of vacci unvaccinated, red ones for AstraZeneca vaccinated compared to unvaccinated and yellow lines are for Pfizer vaccinated
compared to unvaccinated. Darker lines are for calibrated hazard ratios. Vertical black line marks the H compared to unvaccinated. Darker lines are for calibrated hazard ratios. Vertical black line marks the HR = 1 threshold. In
the left panel HR are for PCR testing, central and right panel for different COVID-19 definitions: compared the left panel HR are for PCR testing, central and right panel for different COVID-19 definitions: only PCR positive and PCR positive are diagnose, respectively.
Positive or a diagnose, respectively.
Target trial

the left panel HR are for PCR and R are for PCR testing, the left panel in the left panel in the positive or a diagnose, respectively.
Target trial emulations
Figure 6 shows the results of the target trial emulations based Farget trial emulations
Figure 6 shows the results of
lowest bias and best statistica Target trial emulations
Figure 6 shows the res lowest bias and best statistical power. For ChAdOx1, we successfully replicated the results of vaccine effectiveness against COVID-19 PCR/diagnosis, with the calibrated estimate being closer to the trial result. As for BNT162b2, the observational estimates replicated both the 3- and the 12-week trial result. As for BNT162b2, the observational estimates replicated both the 3- and the 12-week trial

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

results only when calibrated results were used. Uncalibrated HRs overestimated effectiveness at
week 3, and seemed to underestimate it at week 12 after first-dose vaccination.

3 Figure 6. Trial emulation. Calibrated and uncalibrated relative risk for COVID-19 PCR and COVID-19 PCR and/or diagnose.
For AstraZeneca trial individuals with a positive test within the first 21 days were eliminated. For AstraZeneca trial individuals with a positive test within the first 21 days were eliminated.

It is made available under a CC-BY 4.0 International license.

In this large cohort study using data from UK primary care records, we assessed the effectiveness of
the first dose of the widely used COVID-19 vaccines BNT162b2 and ChAdOx1 using overlap weighting. Our estimates of vaccine effectiveness are in line with trial estimates for the ChAdOx1 vaccine (57%) and BNT162b2 at 3 weeks (77%), as well as the JCVI estimates for BNT162b2 at 12 vaccine (57%) and BNT162b2 at 3 weeks (75%), as well as well as the JCVI estimates for BNT162b2 at 12
weeks (75%). weeks (75%).
We chose overlap weighting for the target trial emulation, following an extensive investigation of

the performance of different methods to account for confounding when studying COVID-19 vaccine effectiveness using observational data. Notably, merely including individual-level patient characteristics in the construction of PS did not guarantee the balance of population-level geographic variables, such as geographical region and GP, regardless of subsequent PS approaches of matching or weighting. Also, even if these geographic variables were incorporated into the propensity score, balance between groups was not sufficiently achieved using any of the studied methods, except for overlap weighting and matching. Additionally, negative control outcomes demonstrated a better resolution of uncontrolled confounding and systematic error with overlap weighting compared to other matching and weighting methods. Although no remarkable differences were seen in the final estimates of vaccine effectiveness based on this single database, the proposed theoretical advantages of overlap weighting(14, 21), including exact balance of every measured patient characteristics and good retainment of sample size, were supported by this empirical study. For the first time, we showed that overlap weighting overperforms other weighting and matching methods in terms of unmeasured confounding.

Importantly for COVID-19 vaccine effectiveness, overlap weighting was also the best performing method to minimise confounding at the population-level, including geographic location, which has important implications due to known differences in the spread of SARS-CoV-2 during the study period. Previous early vaccine effectiveness studies using observational data overlooked the adjustment of geographic information(24, 25). Our study, consistent with previous methodological literature, showed that geographic distributions between the vaccinated and unvaccinated individuals were markedly different(26), emphasizing the need for adjustment in vaccine effectiveness studies, given known differences in community transmission levels during the study period. In addition, the insufficient covariates' balance after applying conventional methods highlighted the importance of the proposed diagnostics in observational studies of vaccine effectiveness. More importantly, our findings didn't support the previous suspicion that less active health-seeking behaviour in unvaccinated people might confound the vaccine effectiveness observed in real-world data(12), as no association was found between vaccination and PCR testing in observed in real-world data $(2n)$, as no association was found between vacancient α and β in

It is made available under a CC-BY 4.0 International license.

our study after the empirical calibration. The observed protective vaccine effects shortly after
vaccination were in line with previous findings from observational data(11, 12), which might be attributable to differences in personal behaviour during the period immediately before and after vaccination, e.g. mask wearing, avoiding crowed indoor places/shielding, rescheduling vaccination if feeling unwell, which unfortunately was unlikely to be captured by electronic health records. feeling unwell, which under the captured by electronic health records. The captured by electronic health records.
The cords of the cords of the cords of the cords. The cords of the cords of the cords. The cords of the cord

Conclusions

Our study found vaccination with a first vaccine dose against COVID-19 associated with a 69%
reduced risk of COVID-19 for both the ChAdOx1 and BNT162b2 vaccines. These data therefore confirm the estimation by JCVI that one dose of BNT162b2 provide protection beyond the 3-week period studied in pivotal trials. Secondly, we demonstrate that the studied propensity score weighting and matching methods can replicate pivotal trials and therefore provide reliable estimates of vaccine effectiveness. Further, PS-based overlap weights performed better than IPTW or matching in controlling for measured and unmeasured covariates while retaining sample size, and could be proposed as the preferred method for future vaccine effectiveness studies. Finally, our findings illustrate the need to incorporate patient location (e.g. GP practice or region of residence) and related variables (e.g. testing and transmission rates) to minimize community- as well as patientrelated variables (e.g. testing and transmission rates) to minimize community- as well as patientlevel confounding in the study of COVID-19 vaccine effectiveness.

It is made available under a CC-BY 4.0 International license.

References

1. Cabezas C, Coma E, Mora-Fernandez N, Li X, Martinez-Marcos M, Fina F, et al. Associations
of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19
in nursing homes and healthcare in nursing homes and healthcare workers in Catalonia: prospective cohort study. BMJ.

2. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 2021;374:n1868. Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412-23.
3. Whitaker HJ, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Sebastian Pillai P, et al. Pfizer-

3. Whitaker HJ, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Sebastian Pillai P, et al. Pfizer-
BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. J Infect. 2022;84(5):675-83.
4. Marine EMF, Hulme WJ, Keogh RH, Palmer TM, Williar

Horne EMF, Hulme WJ, Keogh RH, Palmer TM, Williamson EJ, Parker EPK, et al. Waning individuals in contract the control of the control of the Horne EMF, Hulme WJ, Keogh RH, Palmer TM, William
effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines of effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose:
OpenSAFELY cohort study using linked electronic health records. BMJ. 2022;378:e071249.

OpenSAFELY cohort study using linked electronic health records. BMJ. 2022;378:e071249.
5. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat 5. Med. 2022; 28(4): 831-7
6. Monge S, Roias-

Monge S, Rojas-Benedicto A, Olmedo C, Mazagatos C, José Sierra M, Limia A, et al. Med. 2022;28(4):831-7. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.:
variant in Spain: a nationwide cohort study. The Lancet Infectious Diseases. 2022. variant in Spain: a nationwide cohort study. The Lancet Infectious Diseases. 2022.
7. Hulme WJ, Williamson EJ, Green ACA, Bhaskaran K, McDonald HI, Rentsch CT, et al.

7. Hulme WJ, Williamson EJ, Green ACA, Bhaskaran K, McDonald HI, Rentsch
Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in hea Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and so
workers in England: cohort study using OpenSAFELY. BMJ. 2022;378:e068946. workers in England: cohort study using OpenSAFELY. BMJ. 2022;378:e068946.
8. Xie J, Feng S, Li X, Gea-Mallorqui E, Prats-Uribe A, Prieto-Alhambra D. Comparative

workers in England: considering of the study of the study of the Maria Sarah.
8. Cohort Study Fengland: consider study using OpenSafectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in peop effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50. N
Commun. 2022;13(1):1519. Commun. 2022;13(1):1519.
9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy

of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
10. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et a

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and 10. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et a
efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an inte efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis c
randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269): randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
11. Thygesen JH, Tomlinson C, Hollings S, Mizani MA, Handy A, Akbari A, et al. COVID-19

randomised controlled trials in Brazil, South Africa, and the UK. Africa, and the UK. Thygesen JH, Tomlinson C, Hollings S, Mizani MA, Handy A, Akbari A, et al. COVID-19
trajectories among 57 million adults in England: a c trajectories among 57 million adults in England: a cohort study using electronic health record
Lancet Digital Health. 2022;4(7):e542-e57. trancet Digital Health. 2022;4(7):e542-e57.
12. Ostropolets A, Hripcsak G. COVID-19 vaccination effectiveness rates by week and sources of

Lancet Digital Health. 2022;4(1):2022
12. Ostropolets A, Hripcsak G. COVID-1
bias. medRxiv. 2021. bias. medRxiv. 2021.
13. Orteikin D, Patel M. Evaluation of COVID-19 vaccine effectiveness: World Health Organization

bias. medRxiv. 2021. Interim Guidance 2021 [Available from: <u>https://www.who.int/publications/i/item/WHO-2019-nCoV</u>
vaccine effectiveness-measurement-2021.1]

14. Thomas LE, Li F, Pencina MJ. Overlap Weighting: A Propensity Score Method That Mimics vaccine_effectiveness-measurement-2021.1].
14. Thomas LE, Li F, Pencina MJ. Overlap Weighting: A Propensity
Attributes of a Randomized Clinical Trial. JAMA. 2020;323(23):2417-8.

15. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of 15. Austin PC, Stuart EA. Moving towards best practice when using
treatment weighting (IPTW) using the propensity score to estimate cau 15. Australian Properties and the moving of the study of the study in the single studies, probability of the studies of the properties best probability of the studies of the properties of the studies. Stat Med. 2015;34 (28 observational studies. Stat Med. 2015;34(28):3661-79.
16. Public Health England. Annex A: Report to JCVI on estimated efficacy of a single dose of

16. Public Health England. Annex A: Report to JCVI
Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a sin Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a single dose of ChAdOx1 vaccine (AZD1222)
[Available from:

[Available from:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file https://assets.pu
/949505/annex-a https://assets.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishing.publishin /949505/annex-a-phe-report-to-jcvi-on-estimated-efficacy-of-single-vaccine-dose.pdf].

17. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data
18. Overhage Safety surveillance research. J Am Med Inform Assoc. 2012;19:54-60.
18. Oepartment of Health and Social Care. Joint Commit 17.

advice on priority groups for COVID-19 vaccination, 30 December 2020 2020 [Available from: https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccinationadvice-from-the-jcvi-30-december-2020/joint-committee-on-vaccination-and-immunisation-adviceon-priority-groups-for-covid-19-vaccination-30-december-2020].
19. Li X. Lai LY. Ostropolets A. Arshad F. Tan EH. Casaiust P. e

Li X, Lai LY, Ostropolets A, Arshad F, Tan EH, Casajust P, et al. Bias, Precision and Timeliness on-priority-corresponded and the control of the control of Historical (Background) Rate Comparison Methods for Vaccine
of Historical (Background) Rate Comparison Methods for Vaccine 19. Li The Line of the Line Pressent, Arshad F, Tan En, Tan Englash F, Tan Englash P, Casadian Annumers of Historical
19. Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical
Multi-Da Multi-Database Analysis. Front Pharmacol. 2021;12:773875.
20. GOV.UK Coronavirus (COVID-19) in the UK: UK Coronavirus Dashboard [Available from:

20. GOV.UK Coronavirus (COVID-19) in the UK: UK Coron
https://coronavirus.data.gov.uk/details/download]. https://coronavirus.data.gov.uk/details/download].
21. Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights. Am

https://coronavirus.org.com/marting/coronavirus.com/
21. Li F, Thomas LE, Li F. Addressing Extreme Pro
Epidemiol. 2019;188(1):250-7. 21. Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights.
19 Epidemiol. 2019;188(1):250-7.
22. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting

.
22. Lipsitch M, Tchetgen To
confounding and bias in observ 22. Lipsitch M, The generational studies. Epidemiology. 2010;21(3):383-8.
Confounding and bias in observational studies. Epidemiology. 2010;21(3):383-8.
23. Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Em

confounding and bias in observational studies. Epidemiology. 2010;21(3):383-8. calibration for population-level effect estimation studies in observational healthcare data. Proc Na[.]
Acad Sci U S A. 2018;115(11):2571-7. Acad Sci U S A. 2018;115(11):2571-7.
24. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and

Acad Sci U S A. 2018;115(11):2571-7. 24. Menni C, Menni C, May A, Political J, Capacities, 2001. Symptom Study app in the UK: a
SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a
prospective observational study. The La prospective observational study. The Lancet Infectious Diseases. 2021;21(7):939-49.
25. Pitchings MDT, Ranzani OT, Dorion M, D'Agostini TL, de Paula RC, de Paula OFP, et al.

.
25. Hitchings MDT, Ranzani OT, Dorion M, D'Agostini TL, de Paula RC, de Paula OFP, et al.
Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulatio
Sao Paulo. Nat Commun. 2021;1

Sao Paulo. Nat Commun. 2021;12(1):6220.
26. Beleche T, Kolbe A, Bush L, Sommers B. Unvaccinated for COVID-19 but Willing: 26. Beleche T, Kolbe A, Bush L, Somme
Demographic Factors, Geographic Patterns, Demographic Factors, Geographic Patterns, and Changes Over Time 2021 [Available fror
https://aspe.hhs.gov/reports/unvaccinated-willing-ib]. https://aspe.hhs.gov/reports/unvaccinated-willing-ible https://aspe.hhs.gov/reports/unvaccinated-willing-ib].

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Contributors and sources
MC led data analyses and contributed to analytical choices and study design. DPA and AMJ led the conceptualization of the study with contributions from EB and TRM. EB and TRM led the statistical analysis plan jointly with MC, DPA and AMJ. AD mapped and curated the data. MC, JX, DPA and AMJ wrote the first draft of the manuscript. All authors read, made contributions, and approved the last version of the manuscript. DPA and AMJ obtained the funding for this research. version of the manuscript. DPA and AMJ obtained the funding for this research.
Ethics approval

Ethics approval

The study protocol was approved through the CPRD's Research Data Government Process (Protocol)
No 21_000557).

medale (1990).
Funding

The project was supported by the National Institute for Health and Care Research (NIHR) Grant
number COV-LT2-0006.

Conflict of Interest
.

DPA receives funding from the UK National Institute for Health and Care Research (NIHR) in the form group has received funding from the European Medicines Agency and Innovative Medicines Initiative. His research group has received research grant/s from Amgen, Chiesi-Taylor, GSK, Novartis, and UCB Biopharma. His department has also received advisory or consultancy fees from Amgen, Astellas, Astra Zeneca, Johnson and Johnson, and UCB Biopharma; and speaker fees from Amgen and UCB Biopharma. Janssen and Synapse Management Partners have supported training Amgen and UCB Biopharma. January and U_{CB} Biophysis management Partners have supported training programmes organised by DPA's department and open for external participants organized by his
department outside the submitted work.

department outside the submitted work. Data sharing.

Data were obtained from CPRD under the CPRD multi-study license held by the University of Oxford
after Research Data Governance (RDG) approval. Direct data sharing is not allowed.

after Research Data Governments
Acknowledge ments Acknowledgements

This study is based in part on data from the Clinical Practice Research Datalink obtained under
license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the authors alone. $\mathbb D$ conclusions contained in this study are those of the authors alone.T

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Supplementary material:

1. Clinical definition and concept list

 $\begin{array}{c} \n\end{array}$

Table S3. List of concept id included in COVID-19 clinical diagnosis definition. $\overline{1}$

It is made available under a CC-BY 4.0 International license.

 $\begin{array}{c} \n\end{array}$

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

2. Vaccine specific analyses

2.1. Index dates

Figure S1. Index date distribution. (A) AstraZeneca – unvaccinated comparison. (B) Pfizer – unvaccinated comparison. (C) AstraZeneca – unvaccinated weighted and matched cohorts. (D) Pfizer – unvaccinated weighted and matched cohorts.

It is made available under a CC-BY 4.0 International license.

2.2. Cohort counts

Figure S2. Cohorts building flowchart in AztraZeneca and unvaccinated comparison. (A) Flowchart to build the AstraZeneca vaccinated (AZ) and unvaccinated (UV) initial cohorts. **(B)** Flowchart to build the different weig Astrazencea vacemated (Az) and unvacemated (OV) initial cohorts. (B) Flowchart to build the different matching cohorts are for AZ vaccinated cohort and light for unvaccinated. (C) Flowchart to build the different matching the start point of these cohorts is the end of panel at the start point of these cohorts is the end of panel A. Dark blue numbers are for panel A. Dark blue numbers are for P_{S_1} and P_{S_2} are the propensity scores

Figure S3. Cohorts building howchart in Theer and unvaccinated comparison. (A) Flowchart to build the Theer vaccinated (PF) and unvaccinated (UV) initial cohorts. (B) Flowchart to build the different weighting cohorts, the (PF) and any accurated (UV) initial cohorts. (B) Flowchart to build the different weighting cohorts, the start point of these cohorts is the end of panel A. Dark blue numbers are for PF vaccinated cohort and light for unv build the different matching cohorts, the start point of these cohorts is the end of panel A. PS_1 and PS_2 are the propensity scores (PS) computed at the start and index date, respectively. *At this step individuals wi build the different matching control the different matching corres (PS) computed at the start and index date, respectively. *At this step individuals with a record of both ChAdOx1 and BNT162b2 vaccines at the index date we $\texttt{BNT162b2}\text{ vaccines at the index date were excluded.}$

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

2.3. Standardized mean differences

Table S5. SMDs unvaccinated vs vaccinated comparison. Only the 23 covariates with standardized mean differences greater than 0.1 are shown. 3 different periods are defined: short (-30 to -1 respect index date), mid (-180 t

Table S6. SMDs AZ vaccinated vs unvaccinated comparison. Only the 25 covariates with standardized mean differences greater than 0.1 are shown. 3 different periods are defined: short (-30 to -1 respect index date), mid (-18

It is made available under a CC-BY 4.0 International license.

Table S7. SMDs PF vaccinated vs unvaccinated comparison. Only the 27 covariates with standardized mean differences greater than 0.1 are shown. 3 different periods are defined: short (-30 to -1 respect index date), mid (-18

Figure S4. Standardized mean differences (SMD) for the different methods in AstraZeneca vaccinated and unvaccinated
comparison. (A) Scatter plot to compare unadjusted smd to weighted ones. Region and GP surgery are the onl

Figure S5. Standardized mean differ
comparison. (A) Scatter plot to comp
. Figure S5. Standardized mean differences (SMD) for the different methods in Pfizer vaccinated and unvaccinated comparison. (A) Scatter plot to compare unadjusted smd to weighted ones. Region and GP surgery are the only covariates

utcomes distribution Figure S6. Negative control outcomes (NCO) hazard ratios and standard deviation for the AstraZeneca – unvaccinated
comparison. Each blue dot represents a different NCO. Purple dashed are the significative threshold for the positively correlated if they are on the right of the dashed line and negatively on the left. Orange lines mark significance
thresholds after calibration. positive linesholds after calibration.
Thresholds after calibration.

 ϵ Figure S7. Negative control outcomes (NCO) hazard ratios and standard deviation for the Pfizer – unvaccinated
comparison. Each blue dot represents a different NCO. Purple dashed are the significative threshold for the NCO; positively correlated if they are on the right of the dashed line and negatively on the left. Orange lines mark significance
thresholds after calibration. positive linesholds after calibration.
Thresholds after calibration.

It is made available under a CC-BY 4.0 International license.

3. Hazard ratio values

Figure 38. Hazard ratio for the control outcomes during an the follow-up. Each dot is the hazard ratio (HR) for a different adjustment computed with a Cox proportional hazards regression. Blue lines are for any type of vac adjustment compared to unvaccinated compared to unvaccinated and yellow lines are for Pfizer vaccinated compared to unvaccinated. Darker lines are for calibrated hazard ratios. Vertical black line marks the HR = 1 threshol compared to unvaccinated. Darker lines are for calibrated hazard ratios. Vertical black line marks the HR = 1 threshold. In
the left panel HR are for PCR testing, central and right panel for different COVID-19 definitions: the left panel HR are for PCR testing, central and right panel for different COVID-19 definitions: only PCR positive and PCR
positive or a diagnose, respectively.
Table S8. Hazard ratio values corresponding to figure 5. Ha

the left panel HR are for PCR central and right panel for different COVID-19 definitions: only PCR points: and
positive or a diagnose, respectively.
Table S8. Hazard ratio values corresponding to figure 5. Hazard ratios we positive or a diagnose, respectively.
Table S8. Hazard ratio values corres
regression censoring at day 10. $\frac{1}{1}$

|
|
| Figure S10. Kaplan Meier plots for COVID-19. Kaplan Meier plots using overlap weighting with PSGP for COVID-19 PCR test
positive definition. positive definition.